Crawford bolsters US presence

Knutsford-based Crawford Healthcare has expanded its US market presence after acquiring rights to sell products from Canada’s Exciton Technologies.

The supplier of dermatology and wound-care products has signed a long-term agreement with Exciton to exclusively licence their Exsalt product.

Crawford will take over Exciton’s current US operations including its salesforce.

Richard Anderson, CEO of Crawford Healthcare, said: “The agreement with Exciton further expands the Crawford Healthcare portfolio. The Exsalt® products are perfect additions to our current operation and give us further scope to operate in the burns category. We plan to extend the use of this technology in the Woundcare Category.

“Crawford has taken steps to enter the US market with a number of products in Woundcare and Pressure Relief. This agreement with Exciton will allow us to accelerate our plans in the US and build a much larger salesforce presence.

“Our UK sales are growing strongly and our International expansion is gaining momentum with between 10-14 new territories opening up in 2013.”

Rod Precht, President and founder of Exciton Technologies, added: “Partnering with Crawford made sense as the market conditions are ideal to partner with a strong and growing global company who can help take our products to the next level.

“This arrangement allows Exciton to focus on the development of new products based on its technology platform and increase manufacturing efficiencies to maintain the competitive advantage we have created.”

Crawford Healthcare has more than 15 years experience in supplying specialist dermatology and woundcare products to the NHS including KerraMax Care, KerraPro, the QV Skincare range and the SunSense protection range. This deal is the 10th acquisition or licencing deal Crawford has done since 2011.